These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27550143)

  • 21. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 22. A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.
    Wilson CG; Ramage M; Fagan EB
    J Rural Health; 2021 Jan; 37(1):169-171. PubMed ID: 32277732
    [No Abstract]   [Full Text] [Related]  

  • 23. The development and implementation of a rapid-access long-acting injectable buprenorphine clinic in metropolitan Melbourne during the COVID-19 pandemic.
    Straub A; Pastor A; Lloyd-Jones M; O'Neill H; Bonomo Y
    Drug Alcohol Rev; 2021 May; 40(4):681-682. PubMed ID: 32898928
    [No Abstract]   [Full Text] [Related]  

  • 24. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physician-Delegated Unobserved Induction with Buprenorphine in Pharmacies.
    Green TC; Serafinski R; Clark SA; Rich JD; Bratberg J
    N Engl J Med; 2023 Jan; 388(2):185-186. PubMed ID: 36630629
    [No Abstract]   [Full Text] [Related]  

  • 26. Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward.
    Breen CT; Fiellin DA
    J Law Med Ethics; 2018 Jun; 46(2):272-278. PubMed ID: 30147002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.
    Krawczyk N; Picher CE; Feder KA; Saloner B
    Health Aff (Millwood); 2017 Dec; 36(12):2046-2053. PubMed ID: 29200340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Shelby Clinic Medication-Assisted Treatment for Opioid Addiction.
    Penn CL
    J Ark Med Soc; 2016 Aug; 113(2):30-32. PubMed ID: 30047628
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program.
    Payne BE; Klein JW; Simon CB; James JR; Jackson SL; Merrill JO; Zhuang R; Tsui JI
    Drug Alcohol Depend; 2019 Jul; 200():71-77. PubMed ID: 31103879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Buprenorphine maintenance therapy in opioid-addicted health care professionals.
    Newman RG
    Mayo Clin Proc; 2012 Aug; 87(8):804-5; author reply 806-8. PubMed ID: 22862869
    [No Abstract]   [Full Text] [Related]  

  • 31. Implementing Opioid Agonist Treatment in Correctional Facilities.
    Fiscella K; Wakeman SE; Beletsky L
    JAMA Intern Med; 2018 Sep; 178(9):1153-1154. PubMed ID: 30073242
    [No Abstract]   [Full Text] [Related]  

  • 32. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine maintenance therapy in opioid-addicted health care professionals returning to clinical practice.
    Fiscella K
    Mayo Clin Proc; 2012 Aug; 87(8):806; author reply 806-8. PubMed ID: 22862872
    [No Abstract]   [Full Text] [Related]  

  • 34. Buprenorphine in primary care: perspectives on clinical and research priorities.
    Rottnek F; Scherrer JF
    Fam Pract; 2019 Nov; 36(6):677-679. PubMed ID: 31536619
    [No Abstract]   [Full Text] [Related]  

  • 35. Opioid substitution therapy for dependent health care practitioners: approach with caution.
    Earley PH
    Mayo Clin Proc; 2012 Aug; 87(8):803-4; author reply 806-8. PubMed ID: 22862867
    [No Abstract]   [Full Text] [Related]  

  • 36. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
    Parrino MW; Maremmani AG; Samuels PN; Maremmani I
    J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The science and practice of medication-assisted treatments for opioid dependence.
    Pecoraro A; Ma M; Woody GE
    Subst Use Misuse; 2012; 47(8-9):1026-40. PubMed ID: 22676570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buprenorphine maintenance therapy in opioid-addicted health care professionals returning to clinical practice: a hidden controversy.
    Selzer J; Stancliff S
    Mayo Clin Proc; 2012 Aug; 87(8):805-6; author repply 806-8. PubMed ID: 22862870
    [No Abstract]   [Full Text] [Related]  

  • 39. Update on pharmacotherapy for treatment of opioid use disorder.
    Ayanga D; Shorter D; Kosten TR
    Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Number Needed to Prescribe - What Would It Take to Expand Access to Buprenorphine?
    Poorman E
    N Engl J Med; 2021 May; 384(19):1783-1784. PubMed ID: 33983689
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.